Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2018-12-20 M&A Activity
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
S-4
M&A Activity Classification · 95% confidence The document is a Form S-4 registration statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. The text discusses a proposed merger between Arsanis, Inc. and X4 Pharmaceuticals, Inc., detailing the merger agreement, exchange ratios for stock, and ownership percentages post-merger. It includes legal and financial details typical of merger-related filings. The presence of the Form S-4 and detailed merger terms clearly indicate this is related to M&A activity. Therefore, the document should be classified under the M&A Activity category (Code: TAR). The document length (15,000 characters) and content confirm it is the actual filing, not just an announcement or proxy statement. Confidence is high due to explicit references to merger agreement, exchange ratios, and SEC Form S-4.
2018-12-20 English
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a merger agreement amendment, a patent license and option agreement, and references to proxy statements and registration statements related to the merger. It does not contain full financial statements or detailed financial performance data. Instead, it reports on material definitive agreements and other significant corporate events. The presence of merger-related agreements and the nature of the filing indicate it is related to merger activity announcements. Therefore, the document fits best under the category of M&A Activity (TAR).
2018-12-20 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a First Amendment to a Merger Agreement, a patent license and option agreement, and references to proxy statements and registration statements related to a merger transaction. It does not contain full financial statements or detailed financial performance data. Instead, it focuses on merger-related agreements and disclosures. The presence of merger agreement amendments and related transaction information aligns with filings related to merger and acquisition activities. Therefore, the document is best classified under Merger & Acquisition (MA).
2018-12-20 English
SCHEDULE 13D
Major Shareholding Notification
2018-12-06 English
FORM 4 SUBMISSION
Director's Dealing
2018-11-29 English
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 27, 2018, by Arsanis, Inc. It reports a joint investor conference call discussing a merger agreement with X4 Pharmaceuticals, Inc. The document includes a transcript of the conference call as an exhibit. The content focuses on merger-related communications and disclosures, including proxy solicitation information and forward-looking statements about the merger. The presence of a conference call transcript as an exhibit and the focus on merger communications indicate this is related to merger activity filings. The document is not a full annual or quarterly report, nor is it a proxy statement or solicitation itself, but a current report on merger-related events. Therefore, the most appropriate classification is M&A Activity (TAR).
2018-11-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.